Robust Markers and Sample Sizes for Multicenter Trials of Huntington Disease

OBJECTIVE: The identification of sensitive biomarkers is essential to validate therapeutics for Huntington disease (HD). We directly compare structural imaging markers across the largest collective imaging HD dataset to identify a set of imaging markers robust to multicenter variation and to derive...

Descripción completa

Detalles Bibliográficos
Autores principales: Wijeratne, Peter A., Johnson, Eileanoir B., Eshaghi, Arman, Aksman, Leon, Gregory, Sarah, Johnson, Hans J., Poudel, Govinda R., Mohan, Amrita, Sampaio, Cristina, Georgiou‐Karistianis, Nellie, Paulsen, Jane S., Tabrizi, Sarah J., Scahill, Rachael I., Alexander, Daniel C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187160/
https://www.ncbi.nlm.nih.gov/pubmed/32105364
http://dx.doi.org/10.1002/ana.25709

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187160/
https://www.ncbi.nlm.nih.gov/pubmed/32105364
http://dx.doi.org/10.1002/ana.25709

Ejemplares similares